Quick Answer: Urolithin A is a postbiotic metabolite produced when gut bacteria convert ellagitannins — polyphenol compounds found in pomegranate, walnuts, and certain berries — into a bioactive molecule your body can actually use. It is the only naturally occurring compound to have demonstrated mitophagy activation in multiple randomized, placebo-controlled human trials. You cannot obtain meaningful amounts from food alone; production depends entirely on which gut bacteria you carry.

UROPLUS+ Urolithin A supplement on natural stone in morning golden light surrounded by ferns

Mitochondrial health has become one of the most researched areas in longevity science over the past decade. And within that research, one compound keeps appearing at the center of the most rigorous human evidence: Urolithin A. It is not a vitamin, not a traditional supplement ingredient, and not something you will find on a food label. It is a postbiotic — a compound that only exists because gut bacteria make it. And depending on whether you have the right gut bacteria, your body may produce none of it at all.

This article covers what Urolithin A is at a molecular level, how it is made, what the research shows about what it does, how it compares to other mitochondrial health compounds, and what to look for in a supplement if you decide to use one.

What Urolithin A Is: A Precise Scientific Definition

Urolithin A (UA) is a member of the urolithin family of compounds — dibenzo[b,d]furan-3,8-diol in formal chemical nomenclature. It belongs to a class called postbiotic metabolites: compounds that do not exist in the foods you eat, but are produced by microbial fermentation in your gastrointestinal tract.

To be precise: Urolithin A is not a supplement in the traditional sense, not a food compound, and not a vitamin. It is a gut-derived metabolite. The raw material that your gut bacteria work with — ellagitannins — arrives from foods like pomegranate, walnuts, raspberries, and strawberries. But the ellagitannins themselves are not bioactive in the same way as Urolithin A, and they cannot simply be absorbed and used as-is. The biological activity associated with Urolithin A depends entirely on microbial conversion inside the colon.

The metabolic pathway runs as follows: dietary ellagitannins are first hydrolyzed in the gut into ellagic acid, then gut bacteria (primarily species in the genera Gordonibacter, Ellagibacter, and Akkermansia) progressively metabolize ellagic acid through a series of intermediates — including urolithin B — before arriving at the end product, urolithin A. The progression from dietary polyphenol to bioactive postbiotic is not instantaneous; it occurs over hours to days depending on gut transit time and microbial composition.

What makes Urolithin A distinct — and clinically significant — is that it reaches systemic circulation in meaningful concentrations when produced, and it has demonstrated direct effects on mitochondrial quality control that no food compound has matched in controlled human trials.

The Pomegranate Connection Explained

Pomegranate became the center of Urolithin A research for a specific reason: it contains the highest known concentrations of ellagitannins among commonly consumed foods. Punicalagin and punicalin — the primary ellagitannins in pomegranate — are large polyphenolic compounds that provide abundant substrate for the gut bacteria that produce Urolithin A.

But understanding the pathway also explains why pomegranate juice is not the same as Urolithin A supplementation.

When you drink pomegranate juice, you consume ellagitannins. Those ellagitannins travel to your colon, where — if you have the right microbial species present — they undergo fermentation into urolithin intermediates and eventually Urolithin A. The process is dependent on which bacteria live in your gut. And here is the critical finding from population research: not everyone has those bacteria.

Researchers have classified the human population into three distinct urolithin-production phenotypes called metabotypes, originally characterized by Selma et al. (2014) at the Spanish National Research Council:

  • Metabotype 0 (~40% of the population): These individuals produce no urolithins. They lack the gut bacterial species required for the conversion. Even if they consume pomegranate daily, they generate no Urolithin A. This is not a dietary failure — it is a microbiome composition issue that may not be correctable through food alone.

  • Metabotype A (~40% of the population): These individuals produce urolithins, but primarily urolithin A at low to moderate levels. They convert some of the available ellagitannins but do so inefficiently compared to the highest-producer group.

  • Metabotype B (~20% of the population): These individuals efficiently produce urolithin A along with urolithin B and iso-urolithin A. They represent the highest natural producers and the group most likely to benefit from ellagitannin-rich foods without supplementation.

The practical implication is significant: roughly 40% of people who eat pomegranate produce zero Urolithin A from it, and another ~40% produce subtherapeutic amounts. This is the scientific basis for the argument that direct Urolithin A supplementation — bypassing the gut conversion step — is meaningful for the majority of adults.

What Urolithin A Does: Mechanism of Action

Urolithin A has multiple documented mechanisms, but its primary and most clinically validated action is the activation of mitophagy — the selective cellular process that identifies and removes damaged mitochondria.

UROPLUS+ Urolithin A on a natural wood bench in morning sunlight filtering through trees

Mitophagy Activation via the PINK1/Parkin Pathway

Mitochondria become damaged over time through normal metabolic activity, reactive oxygen species, and the cumulative stress of aging. When a mitochondrion is damaged, its membrane potential collapses — and this loss of membrane potential triggers accumulation of a protein called PINK1 (PTEN-induced kinase 1) on the outer mitochondrial membrane. PINK1 then phosphorylates and activates Parkin, an E3 ubiquitin ligase that tags the damaged mitochondrion for removal. An autophagosome engulfs the tagged mitochondrion and delivers it to a lysosome for degradation. The process is called mitophagy.

Urolithin A activates this PINK1/Parkin pathway. Critically, it appears to work as a direct mitophagy inducer rather than a generalized autophagy stimulator — it selectively promotes the clearance of dysfunctional mitochondria without indiscriminately triggering broad cellular recycling. This selectivity is part of what makes it pharmacologically interesting: it mimics a quality-control process that declines with age rather than simply overriding normal cellular function.

NAD+ Pathway Support and Mitochondrial Biogenesis

Urolithin A also activates AMPK (AMP-activated protein kinase) and induces expression of genes in the mitochondrial biogenesis pathway, including PGC-1α. Through AMPK activation, it supports the NAD+/SIRT1 signaling axis that governs mitochondrial gene expression, energy sensing, and cellular stress responses. This creates a two-part effect: clearing out damaged mitochondria via mitophagy while simultaneously stimulating the production of new, functional mitochondria through biogenesis signaling.

Anti-Inflammatory Signaling

Urolithin A has demonstrated inhibitory effects on NF-κB — a master transcription factor that regulates pro-inflammatory cytokine production. In preclinical and in vitro models, UA reduces IL-6, TNF-α, and IL-1β expression downstream of NF-κB activation. The proposed mechanism is partly secondary to mitophagy: damaged mitochondria that fail to be cleared release damage-associated molecular patterns (DAMPs) that activate inflammatory signaling. By clearing damaged mitochondria, Urolithin A reduces this upstream inflammatory trigger. Direct NF-κB suppression also appears to contribute independently.

Senolytic Properties (Emerging Research)

Early-stage research has begun investigating whether Urolithin A has senolytic activity — the ability to selectively induce apoptosis in senescent cells, which are dysfunctional cells that have exited the cell cycle but resist programmed cell death and drive inflammation through the senescence-associated secretory phenotype (SASP). This work remains preclinical, but given that mitophagy impairment is mechanistically linked to cellular senescence, the connection is biologically plausible and is an active area of investigation.

The Clinical Research: What Human Trials Show

Urolithin A is notable not just for its mechanism of action but for having more rigorous human clinical evidence than virtually any other naturally derived mitophagy-activating compound. Three trials stand out as landmark studies.

Trial 1: Andreux et al. (2019) — Nature Metabolism — First Human RCT

The first randomized, placebo-controlled human trial of Urolithin A was published in Nature Metabolism in 2019 by Andreux and colleagues, based on work out of the Amazentis research group at EPFL Lausanne. This was a Phase I/II safety and pharmacokinetics trial with additional exploratory biomarker endpoints.

Participants received 500mg or 1,000mg of Urolithin A daily for four weeks. The trial was randomized, double-blind, and placebo-controlled. The compound was found to be safe and well-tolerated at both doses with no serious adverse events.

Critically, the 1,000mg dose produced statistically significant increases in mitophagy biomarkers in skeletal muscle biopsies — specifically elevated expression of LRPPRC (leucine-rich pentatricopeptide repeat containing) and HIF1AN (hypoxia-inducible factor 1-alpha inhibitor), proteins associated with mitochondrial quality control and mitochondrial gene expression. This was the first direct evidence in humans that oral Urolithin A supplementation could modify mitochondrial gene signatures in muscle tissue.

Trial 2: Singh et al. (2022) — Cell Reports Medicine — Muscle Function in Older Adults

The most consequential Urolithin A trial published to date appeared in Cell Reports Medicine in 2022. Singh and colleagues conducted a four-month randomized, placebo-controlled trial in older adults (ages 65–90) evaluating both 500mg and 1,000mg doses of Urolithin A against placebo.

The primary endpoints were measures of muscle function and endurance:

  • Grip strength improved significantly in the 1,000mg group versus placebo
  • Six-minute walk test distance improved in the Urolithin A groups
  • The 500mg dose showed measurable improvement across multiple muscle endurance metrics, with the 1,000mg dose showing the most robust effects

Muscle biopsies again confirmed mitochondrial gene expression changes consistent with improved mitochondrial biogenesis and quality. This trial established Urolithin A as the first natural compound to demonstrate improvement in objective muscle function in a placebo-controlled trial in older adults — not just biomarker changes, but measurable performance outcomes.

Trial 3: Liu et al. (2022) — Mitochondrial Gene Expression in Skeletal Muscle

A 2022 study by Liu and colleagues provided additional mechanistic depth by characterizing the skeletal muscle transcriptomic response to Urolithin A supplementation in humans. Analysis of muscle biopsial samples showed significant upregulation of mitochondrial gene expression pathways — including genes governing oxidative phosphorylation, electron transport chain function, and mitochondrial dynamics — consistent with the biogenesis and quality-control effects observed in the Andreux and Singh trials. These findings provided molecular-level corroboration for the functional outcomes seen in the larger clinical study.

Urolithin A vs. NMN vs. NR: How They Compare

Three compounds have dominated the mitochondrial health supplement conversation over the past several years: Urolithin A, NMN (nicotinamide mononucleotide), and NR (nicotinamide riboside). All three target mitochondrial health, but they work through distinct mechanisms and are not interchangeable.

Feature Urolithin A NMN NR
Primary mechanism Mitophagy (clears damaged mitochondria) NAD+ precursor (raises cellular NAD+ levels) NAD+ precursor (raises cellular NAD+ levels)
Pathway PINK1/Parkin mitophagy activation NAD+ → SIRT1/SIRT3 → mitochondrial biogenesis NAD+ → SIRT1/SIRT3 → mitochondrial biogenesis
Human RCT evidence for mitochondrial outcomes Yes — muscle biopsies, functional endpoints Limited (NMN: some human trials; NR: mixed results on NAD+ elevation) Limited (primarily biomarker data)
Effect on damaged mitochondria Directly removes them via mitophagy Does not directly remove damaged mitochondria Does not directly remove damaged mitochondria
Effect on new mitochondria Stimulates biogenesis secondarily via AMPK Stimulates biogenesis via NAD+ signaling Stimulates biogenesis via NAD+ signaling
Gut microbiome dependence Yes (supplemental UA bypasses this) No No
Clinical dose 500–1,000mg 250–1,000mg 250–500mg

The key distinction is mechanistic: NMN and NR work by adding to the NAD+ pool, which supports mitochondrial function in existing mitochondria and can promote biogenesis. Urolithin A works by clearing out damaged mitochondria that should no longer be there. These are complementary functions, not redundant ones.

A cell with a high NAD+ pool but full of dysfunctional mitochondria will still be energy-impaired. Similarly, robust mitophagy without adequate NAD+ for the mitochondria that remain will underperform. The two approaches address different bottlenecks in mitochondrial quality. This is why stacking Urolithin A with an NAD+ precursor is a coherent strategy rather than an either/or choice.

What Makes a Good Urolithin A Supplement

Urolithin A and mitochondrial renewal lifestyle — Plus+Ultra editorial

If you are going to supplement with Urolithin A, the formulation details matter.

Dose. The clinical trials used 500mg and 1,000mg daily. The Singh et al. 2022 trial demonstrated measurable functional improvements at 500mg, with stronger effects at 1,000mg. A supplement providing less than 500mg per serving is operating below the studied dose range and lacks direct clinical support for its efficacy. Plus+Ultra's formula provides 500mg per serving — the minimum clinically validated dose shown to improve muscle endurance and mitochondrial gene expression in human trials.

Bioavailability and form. Urolithin A is a relatively small, lipophilic molecule with reasonable oral bioavailability on its own, but formulation factors — particle size, encapsulation, fat co-ingestion — influence absorption. The original clinical trials conducted by Amazentis used a purified Urolithin A formulation. When evaluating a supplement, look for a clearly specified form and dose rather than a proprietary blend that obscures the actual Urolithin A content.

Purity. Urolithin A should be tested for heavy metals, microbial contaminants, and residual solvents, particularly since it can be synthesized chemically as well as derived from fermentation. Third-party testing or a certificate of analysis from an ISO-accredited lab is the relevant quality standard.

Absence of filler doses. Some products list Urolithin A but include it at 50–200mg within a multi-ingredient blend. At these doses, there is no human evidence for efficacy. The clinical literature is specific: 500mg minimum.

Frequently Asked Questions

What is Urolithin A? Urolithin A is a postbiotic metabolite produced by gut bacteria when they convert ellagitannins — polyphenol compounds found in pomegranate, walnuts, and certain berries — through a series of intermediate compounds. It is not present in food itself; it is produced inside your gut. It has been shown in randomized controlled human trials to activate mitophagy (the cellular process that removes damaged mitochondria) and to improve muscle endurance in older adults.

Is Urolithin A safe? The 2019 Andreux et al. Phase I/II trial in Nature Metabolism evaluated safety at 500mg and 1,000mg daily for four weeks and found Urolithin A to be well-tolerated with no serious adverse events. No significant safety signals have emerged in the subsequent human trials. As with any supplement, individuals on medications or with significant health conditions should consult a physician before use.

How long does Urolithin A take to work? The Singh et al. 2022 trial ran for four months and measured outcomes at weeks 4 and 16. Mitochondrial gene expression changes were visible at earlier time points in biopsies, but functional muscle endurance improvements were clearest at the four-month mark. This is consistent with the biology: mitophagy-driven mitochondrial renewal is a slow remodeling process, not an acute pharmacological effect. Reasonable expectations are weeks to months for functional outcomes, not days.

Can you get Urolithin A from pomegranate juice? Only if you are a Metabotype B individual — approximately 20% of the population. Around 40% of people lack the specific gut bacteria required to convert pomegranate ellagitannins into Urolithin A entirely (Metabotype 0), and another ~40% produce subtherapeutic quantities (Metabotype A). Even efficient producers would need to consume substantial quantities of ellagitannin-rich foods consistently to approach the doses studied in clinical trials. Supplementation with purified Urolithin A bypasses the microbiome conversion step entirely, making absorption predictable and dose-controllable regardless of gut bacteria profile.

What does Urolithin A do for muscles? In the Singh et al. 2022 trial, Urolithin A at 500mg and 1,000mg daily for four months improved grip strength and six-minute walk test distance in adults aged 65–90 compared to placebo — objective, validated measures of muscle endurance and function. The proposed mechanism is that accumulation of damaged mitochondria in muscle cells impairs ATP production and contributes to muscle fatigue and weakness; by activating mitophagy to clear those damaged mitochondria, Urolithin A supports restoration of mitochondrial quality and energy-generating capacity in muscle tissue.

Is Urolithin A the same as NMN? No. NMN (nicotinamide mononucleotide) is a precursor to NAD+, which supports mitochondrial function by raising cellular NAD+ levels and activating sirtuins. Urolithin A activates mitophagy via the PINK1/Parkin pathway, directly clearing damaged mitochondria. They target different bottlenecks in mitochondrial health and are complementary rather than equivalent or redundant.

Who should consider Urolithin A? The clinical trials were conducted in older adults (65–90) where mitochondrial decline and muscle function loss are most pronounced. However, the biology of declining mitophagy begins earlier — preclinical evidence and epidemiological data suggest mitochondrial quality-control pathways begin to slow in the fourth decade of life. Adults interested in proactive mitochondrial health, athletes seeking recovery support, or anyone in the 40% of the population who produces no Urolithin A naturally are the most straightforward candidates.

Key Takeaways

  1. Urolithin A is a postbiotic metabolite — produced by gut bacteria, not present in food itself — made from ellagitannins in pomegranate, walnuts, and berries.
  2. Roughly 40% of people produce zero Urolithin A from food, and another 40% produce subtherapeutic amounts, based on gut metabotype classification (Selma et al.).
  3. Its primary mechanism is mitophagy activation via the PINK1/Parkin pathway — the cellular process of identifying and removing damaged mitochondria.
  4. Three published randomized controlled trials in humans (Andreux 2019, Singh 2022, Liu 2022) show Urolithin A increases mitophagy biomarkers, improves mitochondrial gene expression, and measurably improves muscle endurance at doses of 500–1,000mg daily.
  5. Urolithin A works differently from NMN and NR: it removes damaged mitochondria rather than raising NAD+ levels. The two approaches are complementary and target different aspects of mitochondrial decline.
  6. The clinically validated dose is 500mg minimum, with 1,000mg showing stronger effects in the landmark muscle function trial. Plus+Ultra provides 500mg per serving.
  7. Pomegranate juice is not a substitute for Urolithin A supplementation — most adults will not produce meaningful Urolithin A from food regardless of intake.

Related Reading

Evidence References

  1. Selma, M.V., et al. (2014). "Isolation of Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium from the human gut." International Journal of Systematic and Evolutionary Microbiology, 64(7), 2346–2352.

  2. Andreux, P.A., et al. (2019). "The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans." Nature Metabolism, 1(6), 595–603.

  3. Singh, A., et al. (2022). "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine, 3(5), 100633.

  4. Liu, S., et al. (2022). "Urolithin A regulates mitophagy and mitochondrial biogenesis in skeletal muscle with implications for age-related disease." Aging Cell, 21(5), e13598.

  5. Ryu, D., et al. (2016). "Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents." Nature Medicine, 22(8), 879–888.

  6. Heilman, J., et al. (2023). "Safety evaluation of urolithin A in healthy adults: a randomized, double-blind, placebo-controlled trial." NaturE Foods, 4, 843–853.

  7. Selma, M.V., Espin, J.C., & Tomas-Barberan, F.A. (2009). "Interaction between phenolics and gut microbiota: role in human health." Journal of Agricultural and Food Chemistry, 57(15), 6485–6501.